Patients with AIDS and Mycobacterium avium complex (MAC) bacteremia are at high risk for relapse and emergence of resistant isolates during monotherapy with clarithromycin. Ninety-five AIDS patients with MAC bacteremia received clarithromycin plus clofazimine, with or without ethambutol, in a prospective, multicenter, randomized open-label trial. Of 80 patients with positive baseline cultures, sterilization or a 2 log 10 reduction in colony-forming units of MAC in two consecutive blood cultures occurred in 69% of both groups. There were nine relapses in the two-drug arm and three in the three-drug arm. Kaplan-Meier estimates of risk of relapse at 36 weeks were 68% and 12%, respectively (P Å .004). All relapse isolates were resistant to clarithromycin. Median time to clarithromycin resistance was 16 weeks with two drugs and 40 weeks with three drugs (P Å .004). Ethambutol reduced relapses and emergence of clarithromycin resistance and should be considered an essential component of clarithromycin-based therapies for MAC bacteremia.
Disseminated infection with Mycobacterium avium complex
ever, that 16-week study did not investigate for rates of relapse or emergence of drug resistance. (DMAC) remains the most common serious bacterial infection in patients with advanced AIDS. Up to 50% of patients with Clarithromycin has potent microbiologic activity against MAC and appears to be the cornerstone for the treatment of AIDS may ultimately develop this infection [1] , and 21% develop DMAC during the last 6 months of life [2] . DMAC DMAC in AIDS patients [10, 12] . When clarithromycin was administered as monotherapy, resistance to clarithromycin ocis associated with considerable morbidity and contributes to mortality [3, 4] . Antimycobacterial therapy improves sympcurred at a median of 16 weeks and was associated with recurrence of symptoms and signs of disease [11] . Adding additional toms and appears to increase survival [5 -7] . Multidrug combinations that do not contain macrolides reduce symptoms and drugs to clarithromycin could potentially decrease the emergence of clarithromycin-resistant MAC and relapse of bacterthe levels of circulating MAC, but these regimens are associated with high rates of toxicity and only modest efficacy in emia. Both clofazimine and ethambutol have either additive or synergistic activity when combined with clarithromycin in reducing the level of bacteremia [8, 9] . Recently, a combination of clarithromycin, ethambutol, and rifabutin was reported to various in vitro and animal models [13 -16] . In 11 patients with MAC bacteremia treated with clofazimine plus clarithromycin, improve survival compared with a standard regimen of ciprofloxacin, ethambutol, rifampin, and clofazimine [10] . Howblood cultures became sterile after 7 days of treatment, and no relapses were reported after an average of 19 weeks of therapy [17] . Because ethambutol has demonstrable antimycobacterial activity when administered as monotherapy to AIDS patients blood cultures with acid-fast bacilli or MAC obtained within the Statistical analysis. All randomized patients were included in the survival analysis in the analysis of adverse events on an inten-2 months prior to entry, a clinical syndrome highly suggestive of DMAC but blood cultures that had not yet been collected or had tion-to-treat basis. Patients with positive entry blood cultures for MAC and at least one follow-up culture were included in the been incubating for õ3 weeks, or a positive tissue biopsy with MAC but blood cultures that had not yet been collected or had analysis of microbiologic response. Only patients who achieved microbiologic response were included in the analysis of relapse. been incubating for õ3 weeks.
Patients were excluded if they had any one of the following: All patients with positive baseline cultures were included in the analysis of time to clarithromycin resistance. Time to microbiomonotherapy with clarithromycin, azithromycin, clofazimine, or ethambutol for ú1 cumulative month prior to entry; combination logic response, relapse, development of clarithromycin resistance, and death were estimated by the Kaplan-Meier product-limit therapy for ú72 h with two or more agents active against MAC in the month prior to entry; combination therapy against MAC for method with differences assessed by the log-rank test. Differences in the proportion of patients reporting fever at each study visit ú2 weeks at any time prior to entry; life expectancy õ8 weeks; inability or unwillingness to take oral medications; history of sewere compared by the x 2 method or Fisher's exact test (2-tailed), as appropriate. vere macrolide allergy; or a need for ongoing therapy with granulocyte colony-stimulating factor, granulocyte-macrophage colony stimulating factor, or systemic interferon-a or -g. Laboratory ex-
Results
clusion criteria included a total neutrophil count õ500 cells/mm 3 , serum creatinine ú2.5 times the upper limit of normal, and serum Demographics and baseline characteristics. In total, 95 aminotransferase levels ú10 times the upper limit of normal.
patients were enrolled at the four California Collaborative intravenous drug use was more common in patients randomized and randomly assigned from a central site to receive a combination of 1000 mg of clarithromycin twice daily plus 100 mg of clofazito the two-drug arm (22% vs. 4% in the three-drug arm, P Å mine once daily, with or without 400 mg of ethambutol twice .01). Vomiting was more prevalent in the two-drug arm at daily. All study drugs were administered orally. Patients who were baseline (35% vs. 16% in the three-drug arm, P Å .04). Fever receiving combination therapy against MAC for õ72 h had therapy at entry was more commonly reported by patients in the threewithheld for 72 h prior to starting study therapy. Ethambutol was drug arm (80% vs. 63% in the two-drug arm, P Å .07), and arm and three in the three-drug arm. In the two-drug arm, Clarithromycin susceptibility. Of 86 baseline isolates, 65 (76%) were available for susceptibility testing. Because all of Kaplan-Meier estimates of risk of relapse at 24 and 36 weeks were 22% and 68%, respectively. In the three-drug arm, the the isolates that were unavailable for testing were from patients enrolled early in the study, none of whom had received macroKaplan-Meier estimates of risk of relapse at 24 and 36 weeks were 5% and 12% respectively (P Å .004, log-rank test).
Results of quantitative blood cultures for MAC. At entry,
lides for prophylaxis, it was assumed that these baseline isolates were susceptible to clarithromycin. All available baseline isoSymptoms. The proportion of patients reporting fever at entry was higher in the three-drug arm (figure 2). However, lates were susceptible to clarithromycin at a concentration of 8 mg/mL, including 2 from the 3 individuals in the two-drug the proportion of patients reporting fever within 1 week of a study visit in the two-drug arm was significantly higher at each arm who had received prior macrolide prophylaxis (1 of the 3 had negative baseline cultures). All 12 isolates obtained at the visit at weeks 4 -40 (P õ .05, x 2 test or two-tailed Fisher's exact test). More patients reported diarrhea at weeks 20, 28, time of protocol-defined relapse were resistant to clarithromycin. Of 366 isolates obtained after entry, 315 (86%) were and 32 in the two-drug arm, but these differences were not statistically significant (data not shown). The incidence of reavailable for susceptibility testing. Time to development of clarithromycin resistance is shown in figure 3 . Sixteen patients ported sweats was similar in both groups at all time points. in the two-drug arm and 11 in the three-drug arm had a to 500 mg twice daily at some point during the study in 25 (54%) of 46 patients in the two-drug arm and 25 (51%) of 49 clarithromycin-resistant isolate detected. Median time to the development of resistant MAC isolates was 16 weeks in the in the three-drug arm (NS). Adverse events deemed possibly or definitely attributable to study medications were similar in two-drug arm and 40 weeks in the three-drug arm (P Å .004, log-rank test).
both groups. Gastrointestinal events were common, occurring in 23 (50%) of 46 patients assigned to two drugs and 27 (55%) Survival. Survival did not differ between the 2 groups (figure 4). Median survival in the two-drug arm was 31 weeks of 49 assigned to three drugs (NS). versus 39 weeks in the three-drug arm (P Å .5, log-rank test). Discussion Adverse events. There were three treatment-terminating adverse events in the two-drug arm and five in the three-drug This is the first study designed primarily to evaluate the effect of macrolide-based combination therapy on time to rearm (NS, table 3). The dosage of clarithromycin was decreased The addition of clofazimine to clarithromycin did not appear
to improve outcome. The median time of 16 weeks to clarithromycin resistance in the two-drug group in this study was similar NOTE. P not significant for all comparisons between 2-and 3-drug arms.
to the median time of 16 weeks with clarithromycin monotherapy in ACTG 157 [11]; this was true even though the median baseline cfu in our two-drug arm of 1.1 log 10 was considerably lower than the value of 2.7 log 10 in the ACTG 157 study, lapse and emergence of clarithromycin resistance during treatment for MAC bacteremia. We found that the three-drug compossibly due to increased awareness and earlier diagnosis of MAC. In patients with high tissue burdens of MAC, mutations bination that included ethambutol was superior to a two-drug combination without ethambutol for the prevention of microbi- [27] conferring resistance to clarithromycin and cross-resistance to azithromycin may begin to emerge well before tissue ologic relapse of MAC bacteremia in patients with AIDS. The development of clarithromycin resistance was also significantly levels of clofazimine have accumulated sufficiently to inhibit MAC growth. The apparent lack of supplemental benefit of delayed in the patients receiving the three-drug regimen (median, 40 vs. 16 weeks for the two-drug arm). Furthermore, the clofazimine was surprising in view of the excellent activity of clarithromycin plus clofazimine in the beige mouse model [13] . three-drug combination resulted in symptomatic benefit, with a lower incidence of patient-reported fever at weeks 4 -40.
Ji et al. [28] have postulated that clofazimine may appear more active in this model due to carryover of large quantities of These results are consistent with in vitro and in vivo studies showing that ethambutol augments the antimycobacterial activaccumulated clofazimine from organs to culture media [28] , although the importance of this observation has been disputed ity of clarithromycin [13 -16] and the recent report that ethambutol delays emergence of clarithromycin resistance in the [29] . Because clofazimine does not appear to add appreciable activity to clarithromycin alone and has been associated with beige mouse model of MAC [21] . In addition, ethambutol is generally well tolerated in patients with AIDS. Similarly, in increased mortality in a recently completed trial [30] , the US Food and Drug Administration has advised that clofazimine our study, ethambutol at 400 mg twice daily did not increase the incidence of adverse events compared with the two-drug should not be used for the initial treatment of MAC. We used an initial dosage of clarithromycin of 1000 mg combination.
In the AIDS Clinical Trials Group (ACTG) study 157, in twice daily, which was reduced at some time during the study to 500 mg twice daily in about half of the patients, due to which clarithromycin was administered as monotherapy, MAC isolates resistant to clarithromycin were isolated early in the gastrointestinal side effects. In a study of clarithromycin monotherapy at 500, 1000, and 2000 mg twice daily, patients course of therapy (median, 16 weeks) and were associated with recrudescence of symptoms [11] . Measures to reduce the experienced more rapid sterilization of blood cultures at the two higher dosages, but there was no demonstrable effect of incidence of resistance to clarithromycin may be expected, therefore, to result in clinical benefit. However in the current dose on symptoms or emergence of resistance [11] . Moreover, an unexplained increase in mortality during the first 12 weeks study, even our three-drug regimen did not entirely prevent the emergence of resistance. This may be due to inadequate of the study occurred in patients receiving 1000 or 2000 mg twice daily, although a Cox proportional hazards model adantimicrobial potency to prevent outgrowth of resistant mutants JID 1997;176 (November) Combination Therapy for MAC 
